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A b s t r a c t
The lentivirus Equine Infectious Anemia Virus (EIAV) causes 
an acute infection in horses which is characterized by fever, 
viremia, thrombocytopenia, edema, and hemolytic anemia. Most 
horses survive the acute disease, but remain persistently infected 
for life. The exact mechanism whereby horses' control their 
initial infection is unknown, though it appears likely that cellular 
immune mechanisms are involved. T lymphocytes have been shown 
to play a  major role in the recovery from a  variety of viral 
infections, though their role in EIAV infection has not been 
established. We tested peripheral blood mononuclear cells (PBMC) 
from ElAV-infected ponies for evidence of a  cell-mediated 
immune response to this virus. PBMC from infected ponies 
exhibited ElAV-specific lymphoproliferation upon in vitro 
stimulation with viral antigen. Cytolytic effector cell activity of 
these celts was determined by lectin-mediated cytotoxicity 
assays and by the production of serine esterase. To investigate 
the role of cell-mediated immune responses in protection from 
ElAV-induced disease, the T cell responses to EIAV in vaccinated 
ponies were analyzed. Ponies were vaccinated with an inactivated 
EIAV whole virus vaccine or a  subunit vaccine enriched in EIAV 
envelope glycoproteins. The in vitro lymphoproliferative 
response was shown to be mediated by T lymphocytes and was 
indistinguishable from that induced by EIAV infection. Although 
both vaccines stimulated ElAV-specific cell-mediated immunity,
x
upon in vivo challenge with virulent or avirulent EIAV it was 
determined that the whole virus vaccine conferred protection 
while the subunit vaccine appeared to exacerbate disease. EIAV 
specific cell-mediated immunity was also dem onstrated by 
antigen specific proliferation of T cells from infected and 
vaccinated ponies in response to viral proteins and peptides. By 
identifying the segments of gp90 and gp45 that were reactive in 
these cell-mediated immune response assays, this study will aid 
in the development of possible vaccines against EIAV and other 
related retroviruses including HIV-1.
x i
Chapter I
In troduc t ion
Purpose of the Study 
Lentiviruses cause persistent infections characterized by 
unchecked virus replication in the presence of virus specific 
antibodies (Adams and Bell, 1976). In contrast to other 
lentiviruses models, the horse is capable of limiting virus 
replication during persistent equine infectious anemia virus 
(EIAV) infection. This restriction of virus replication appears to 
be immune-mediated and probably involves cell mediated immune 
responses (Kono, et at., 1976, Perryman, et at., 1988). Thus the 
horse provides a  unique model for identifying protective cell- 
mediated immune responses to lentivirus following infection and 
vaccination.
Equine infectious anemia virus is unique among lentiviruses 
because most horses, although infected for life, are able to 
immunologically control the disease. Determining the area  of the 
immune response responsible for this protection and what viral 
protein(s) elicit this response are of critical importance. One of 
the difficulties in vaccine design with other lentiviruses is the 
natural infection does not lead to protective immunity. In 
contrast, an EIAV vaccine that induces a  similar immune response 
as  natural infection could protect naive horses from EIAV disease.
1
2Due to these unique features, EIAV is an important animal model 
in lentivirus research.
The purpose of this research project was to characterize the 
virus specific cell-mediated immue responses generated in ponies 
sensitive to EIAV either by infection or vaccination. Synthetic 
peptides were used to identify immunologically important 
segments of EIAV glycoproteins. The immune response to gag 
proteins was also studied.
The overall goal of this research project was to identify, 
measure, and characterize cell-mediated immune (CMI) responses 
of ponies infected with EIAV. The value of this research will be in 
characterizing the immune responses that could mediate control 
of the recurrent viremia and associated clinical episodes. This 
study provides new insight in the role of humoral and cell- 
mediated immunity in this persistent infection. By identifying the 
segments of gp90 and gp45 that are reactive in the CMI assays and 
by demonstrating that a  synthetic vaccine against EIAV could 
confer some protection, this study will aid in the development of 
possible vaccines against EIAV and other related retroviruses 
including HIV-1.
Literature Review
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The equine infectious anaemia virus (EIAV) is a  member of 
the family Retroviridae (Issel, et at., 1979; McGuire, et at., 1979). 
This family of single-stranded RNA viruses includes the three 
subfamilies, oncovirinae, spumavirinae, and lentivirinae. All 
three subfamilies of retroviruses use reverse transcription and 
the viral enzyme reverse transcriptase to copy the single strand 
RNA viral gemone into a  double strand DNA intermediate which 
persist in the infected cell either integrated into the host cell 
chromosome or in the episomal form (Jarrett, 1987; Levy, 1986). 
The retroviruses may enter the host cell by an exogenous route in 
which the virus attaches to specific receptors on the cell surface 
and enters through the cell membrane, or by an endogenous route 
in which the virus enters the germ line of the host (Levy, 1986). 
Another feature of this family of viruses is that they mature by 
budding from the plasma membrane of host cell (Issel, et at.,
1979; McGuire, et at., 1979). The genomic organization of all 
retroviruses is similar, encompassing three major genes, the 
group specific antigen (gag), polymerase (pol), and envelope (env).
EIAV is a  member of the subfamily lentivirinae (slow 
viruses), a  group of non-transforming exogenous viruses, which 
also includes Maedi-Visna Virus (MW) of sheep, Caprine Arthritis 
Encephalitis Virus (CAEV), Simian (SIV), Bovine (BIV), Feline (FIV) 
and Human (HIV) immunodeficiency viruses (Pedersen, et at., 1987, 
Jarrett, 1987; Haase, I986; Levy, 1986). The lentiviruses are
4unique in their generation of envelope antigenic variants (Haase, 
1986; Levy, 1986). Characteristics of the d iseases associated 
with these viruses include long incubation periods and the 
establishment of persistent infections (Haase, 1986). This 
retroviral persistence in the host is partially due to the 
incorporation of viral genes into the host chromosomal DNA, 
thereby avoiding the host immune surveillance system (Jarrett, 
1987), and partially due to the generation of envelope antigenic 
variants (Haase, 1986). Lentiviruses have the basic retroviral 
genome which includes flanking long terminal repeats (LTR) with 
promotor and enhancer regions, but the lentiviruses have the 
additional domains, the NRE and the transactivation response 
region (TAR) (Haase, 1986; Rushlow, et at., 1986). The TAR region 
responds to the trans-activating protein (TAT) protein which 
trans activates viral genes and increases viral replication 
(Sherman, et at., 1988; Rushlow, et at., 1986). The genomic 
structure of the retroviruses is composed of regions coding for 
the gag, pol, and env proteins (Levy, 1986). The lentivirus 
subfamily of retroviruses contains overlapping gag and pol genes 
in different reading frames and a  non-overlapping env gene 
(Rushlow, et at., 1986).
The El A virus has a  single stranded RNA genome of about 9 
kilobases and the core nucleoid is enclosed in an lipid containing 
envelope with glycoprotein spikes. The virus is spherical and 
about 100nm in diameter. The virus life cycle involves 
attachment and entry by receptor mediated endocytosis, reverse
5transcription of the viral genome, integration of the DNA into the 
host genome, transcription of the viral proteins with host RNA 
polymerase, translation of the mRNA by the host ribosomes, virion 
assembly, and release by budding through the plasma membrane. 
The genome structure of EIAV includes 6 open reading frames 
(ORF) organized in the following manner, 5' LTR gag pol S1 S2 env 
S3 LTR 3'. The LTR like other lentiviruses is composed of U5, R 
and U3. Unique sequence 5' (U5) is 36 base pairs long and contains 
the primer binding site for tRNA initiation of minus strand 
synthesis (Derse, et a/., 1987). The repeat sequence (R) is 77 base 
pairs long and contains the TAR sequence. Unique sequence 3* is 
189 base pairs long and includes promotors. The S1 gene product 
has been identified as the EIAV TAT. This protein shares 
structural and functional homology with the HIV-1 TAT protein 
(Stephens, eta!., 1990). The S3 gene is believed to encode the 
EIAV Rev (regulator of expression of virion proteins) protein 
(Stephens, et at.,1990). The S2 protein is expressed in infected 
animals, but the function remains unknown (Schiltz, et at., 1992). 
The gag gene codes for the structural proteins of the viral core 
including p15, p26, p11, and p9. These internal core proteins are 
nonglycosylated. The p15 phosphoprotein forms a  continuous inner 
coat of the envelope. The structural protein p26 is the primary 
component of the core shell and is the antigen used in the 
commercial agar gel immunodiffusion (AGID) test (Issel, et at., 
1966). The internal proteins also include the acidic protein p9 and 
the basic protein p11. The pol gene codes for the viral enzymes
6needed for replication, including the reverse transcriptase. The 
predominant antibody response during EIAV persistent infections 
is directed against the two viral envelope glycoproteins, the 
external hydrophilic, highly glycosylated gp 90, and the 
transmembrane hydrophobic, slightly glycosylated gp 45 
(Montelaro, et at., 1984; Issel, et at., 1986; Rushlow, et at., 1966; 
Hussain, et at., 1987).
Equine infectious anemia or swamp fever is a  chronic 
relapsing infectious d isease of horses that persist for life 
(Cheevers, et at., 1985; Issel, et at., 1979). This equine disease is 
found worldwide, and in the United States the highest number of 
cases  are from the gulf coast region (Issel, et at., 1986). The 
clinical characteristics of this d isease are cycles of fever, acute 
hemolytic anemia, depression, edema, anorexia, leukopenia, and 
thrombocytopenia (Issel, et at,, 1984). The anemia results from 
both suppression of erythropoiesis and destruction of 
erythrocytes that are coated with a  viral hemagglutin, the 
antivirus antibody and complement (McGuire, et at., 1990; Issel, et 
at., 1986). EIAV and antibody can form circulating immune 
complexes which elicit fever and cause glomerulonephritis when 
they are deposited in the kidney (Cheevers, et at., 1985; Shively, 
e ta / .,  1982; McGuire, et at., 1979). The thrombocytopenia 
associated with EIA appears to be mediated by the clearance of 
platelets with immune complexes on their surface (Clabough, e t  
at., 1991). The thrombocytopenia in HIV infections is believed to 
be immune mediated, however the exact mechanisms involved have
7not been determined (Riqaud, et al., 1992). Although the immune 
response to EIAV results in clinical disease, immune suppression 
with increased susceptibility to opportunistic infections does not 
occur in EIA. The primary target cell in which the virus replicates 
is the macrophage (McGuire, et a l, 1986). The virus is transmitted 
by the interrupted feeding of insects, primarily the horsefly and 
by the use of contaminated needles (Issel, et al., 1988). The life 
time persistence of this virus in the infected horse is attributed 
to the antigenic variation of the envelope glycoprotein (Payne, et 
al., 1987; Salinovich, e t al., 1986) and to the integration of the 
viral genome into the host genome resulting in latently infected 
cell which are not recognized by the immune system of the host 
(Derse, et al., 1987). The antigenic variation explains the 
recurrent nature of EIA and the failure of classical vaccines 
(McGurie, et al., 1979). Most horses infected with EIAV eventually 
control the disease, though they remain persistently infected. The 
AGID test which accurately demonstrates the presence of 
antibodies to EIAV, is used to identify infected horses. (Issel, et 
al., 1979).
One of the critical questions to answer in lentiviral 
research is which type of immune response is responsible for 
protection against d isease and/or infection (Berzofsky, et al.,
1991). The adaptive immune responses are generally divided into 
humoral and cellular components. The humoral response refers to 
antibody production. B ceils are responsible for producing 
antibody which inactivates celt free virus, that is it neutralizes
8viral infectivity. In addition to neutralizing virus, the antibody 
produced by S cells in combination with complement can lyse 
virus and virus infected cells. Antibody labeled cells can also be 
lysed by various cytolytic effector cell including natural killer 
cells and macrophages. The macrophages also function as antigen 
presenting cells and play a central role in the induction of the 
cellular immune response. While virus specific antibodies may be 
effective in limiting initial viral infections, cell-mediated 
immunity is essential for clearance of the infection. Indeed, 
successful immune response to viral infections is T cell 
dependent, since the antibody response requires T cell help, 
important antiviral cytokines are produced by T cells, and 
cytotoxic T cells are crucial for eliminating intracellular 
infections. The central role of the T cell has been demonstrated in 
various viral infections (Larsen, et a/., 1984; Mitchell, et et.,
1985), and these cells probably play a  similar role in lentivirus 
infections. To assess  the role of CMI in disease, a convenient 
assay for measuring this response is needed. An in vitro assay 
that is considered to correlate with cell mediated immunity in  
vivo is the antigen specific proliferation of lymphocytes. The 
presentation of antigen to T lymphocytes induces cellular 
proliferation that results in the selective expansion of antigen 
specific clones of T cells. Numerous studies demonstrated that 
peripheral blood mononuclear cells (PBMC) from HIV infected 
individuals proliferate in response to in vitro stimulation with 
purified live HIV, inactivated HIV, purified envelope glycoprotein,
9viral antigens and envelope peptides (Berzofsky, et al., 1991; 
Krowka, et al., 1990; Schrier, et al., 1989; Eichberg, et al., 1987; 
Zarling, et al., 1986). Immunization with vaccinia virus 
expressing HIV glycoproteins (Picard, et al., 1992; Zarling, et al.,
1986), HIV envelope glycoprotein vaccine (Keefer, et al., 1991; 
Mannhalter, et al., 1991) and with glycoprotein synthetic peptides 
(Hart, et al., 1991; Berzofsky, et al., 1991; Vahlne, et al., 1991) 
primed recipients for the in vitro antigen-specific proliferative 
response. Besides measuring lymphocyte proliferation, 
quantitative assays have been developed to measure the killing of 
antigen labeled target cells by specific cytotoxic T lymphocytes 
which are an important part of cell-mediated immunity.
Circulating HIV-specific cytotoxic lymphocytes exist in 
asymptomatic seropositive HIV patients and these cells decrease 
a s  the patients clinical status deteriorates (Autran, et al., 1991; 
Hoffenback, et al., 1989). The existence of HIV specific cytotoxic 
lymphocytes in HIV seropositive subjects has been reported using 
target cells labeled with env (gp160) and gag (p55) precursor 
proteins (Riviere, et al., 1989), gag p24 protein ( Koup, et al., 
1991), NEF (Culmann, et al., 1991) and VIF (Riviere, et al., 1989) 
regulatory proteins, and with envelope gp 120 synthetic peptides 
(Dadaglio, et al., 1991). Antibody-dependent cell-mediated 
cytotoxicity (ADCC) to HIV envelope glycoprotein external and 
transmembrane portion has been described (Tyler, et al., 1989; 
Blumberg, et al., 1987). This cytotoxic reaction is mediated by Fc 
receptor bearing kilter cells that recognize target cells with
10
specific antibody bound to their surface. This cytotoxic reaction 
does not involve cytotoxic T lymphocytes and its role in vivo is 
unknown, although it has been suggested that it may be an early 
host response in HIV infections (Tyler, et a/., 1989).
Just as with HIV, the protective immune response and the 
viral proteins involved are not known for other lentiviruses. In 
simian immunodeficiency virus (SIV), there is no correlation 
between levels of neutralizing antibody or levels of ADCC and 
protection of vaccinated animals (Hartung, et a/., 1992; Murphey- 
Corb, eta!., 1989). Since the antibody response alone is probably 
not protective, characterizing the T cell mediated immunity is 
important with this and all lentiviruses. A specific cytotoxic T 
lymphocyte response was demonstrated in animals vaccinated 
with vaccinia SIVmac (Shen, et al., 1991).
Another lentivirus recently described is the feline 
immunodeficiency virus (FIV), which causes an "AIDS” like 
syndrome in cats (Pedersen, et a l, 1987). Very little has been 
reported on FIV or the cell-mediated immune response to this 
virus. There is evidence to suggest that T cell dysfunction is an 
important part of the clinical disease, since lymphocytes from FIV 
infected cats had lower mitogen response that uninfected cats 
(Lin, et a l, 1990).
Equine infectious anemia virus is unique among lentiviruses 
in that most horses, although infected for life, are able to 
immunologically control the disease. Identifying both the immune 
response responsible for this protection and the viral protein(s)
11
which elicit this response is of critical importance for the 
development of a successful vaccine. One of the difficulties in 
vaccine design for other lentiviruses is that natural infection 
does not lead to protective immunity. In EIAV, however, a  vaccine 
that induces a similar immune response as  natural infection could 
protect naive horses from EIAV disease. Due to these unique 
features, EIAV is an important animal model in lentivirus 
research. As with other viruses, there is evidence that cell- 
mediated immunity plays an important role in EIA control. Horses 
that are asymptomatic carriers have episodes of viremia and 
clinical d isease when treated with immuonosuppressive drugs, 
suggesting CMI involvement (Kono, et al., 1976). Additional 
support that immune response controls EIAV disease is found in 
foals lacking functional T and B cells due to combined 
immunodeficiency (CID). These CID foals fail to terminate the 
viremia caused by EIAV, while normal foals become asymptomatic 
carriers (McGuire, et at., 1990; Perryman, eta/., 1988).
Furthermore, there is no correlation between decreased viremia 
and the level of neutralizing antibody, indicating that this is not 
due to B cell function (Rwambo, et at., 1990a). Together, these 
provide in vivo evidence of a  role for cell-mediated immunity in 
the control of EIAV disease during the afebrile carrier stage.
Further evidence for the importance of cellular immunity in 
control com es from studies of antigen specific proliferation of 
PBMC from EIAV infected horses. The lymphoproliferative 
response increases shortly after primary infection, decreases
12
during the asymptomatic phase, but increases with recurrent 
febrile episodes (Kono, et at., 1976a). The cells involved in in 
vitro lymphoproliferation response are T lymphocytes. Nylon 
wool purified T lymphocytes, but not B cells or monocytes, 
respond to EIAV antigen stimulation in vitro (Shively, et at.,
1982). PBMC's from EIAV infected horses are able to kill virally 
infected equine dermal cells in a direct cytotoxicity assay  
suggesting a  potential role for cytotoxic lymphocytes (Fujimiya, 
et at., 1979). As with HIV, ADCC has been suggested to be 
important in the initial immune response to EIAV. ADCC was 
demonstrated against autologous EIAV infected lymphoblasts in 
vitro during the acute, but not the chronic stage of EIAV 
(Qerencer, et at., 1989). Again, the in vivo importance of this 
response is not known. Indeed, ADCC probably contributes little to 
the immune control during the carrier state since it is only 
present at the initial stage of infection. All of this in vivo and in 
vitro evidence supports that cellular immunity plays an important 
role in controlling this lentivirus disease. Nevertheless, the 
specific viral antigens recognized remain unknown.
Chapter II
Materials and Methods
Ponies
Grade ponies ranging from 2 to 7 years of age and weighing 
100 to 300 kg were used in all studies. Prior to entering the 
study the ponies were tested for exposure to EIAV by AGID and 
western blot analysis (Isset, et at., 1988). They were housed in 
screened box stalls within a  screened facility, in order to protect 
from hematophagous insects, and fed a  complete pelleted ration 
(Purina Mills, St. Louis, Mo.). The ponies received routine 
immunizations which included a  tetanus toxoid, inactivated 
Western and Eastern encephalitis viruses, inactivated equine 
influenza viruses A1 and A2, an avirulent spore vaccine for 
anthrax, and a  modified live-virus vaccine for equine 
rhinopneumonitis. They were routinely treated with Ivermectin 
(Merck, Rahway, N.J.) for intestinal parasites. At least 60 days 
passed between the final routine immunization and entry into this 
study. Throughout the study, rectal temperature and clinical 
status were monitored twice daily. Serum, plasma and whole 
blood sam ples were routinely collected aseptically in vacutainer 
tubes by jugular venipuncture.
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Virus Strains 
EIAV virus strains used in this study were generously 
provided by Sue Hagius (Department of Veterinary Science, LSU).
Prototype-ElAV (prototype), derived from the virulent Wyoming 
strain of EIAV, was attenuated by in vitro propagation in primary 
fetal equine kidney (FEK) cells (Issel, et a/., 1988). The prototype 
virus infects ponies, but seldom induces severe clinical disease.
A pathogenic variant of the prototype virus was obtained from a 
Prototype-infected pony and was subsequently propagated in vitro 
in the presence of neutralizing antibodies (Rwambo, et at., 1990b).
In spite of the repeated in vitro passages of this isolate, which 
had undergone two series of endpoint dilution "clonings” in 
addition to its extensive cultivation in equine fibroblastic cells, 
it retains its virulence in ponies and has become our reference 
virulent challenge virus. Its infectivity in ponies was 107 -5 
median horse-infective doses (HID50 ) per ml of cell culture fluid.
This challenge strain was used because of its virulence, its 
purity, and the lack of cross-neutralization between it and the 
prototype cell-adapted strain. Ponies surviving primary 
infections with this strain for 100 days possess neutralizing 
antibodies to the infecting strain but have no detectable 
neutralizing antibody to the prototype strain.
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Cell Preparation 
Peripheral blood samples were obtained from the jugular 
vein and aseptically collected into heparinized (10 U/ml) 
vacutainer tubes. Buffy coat cells were obtained by 
centrifugation (750 x g; 10 min) and resuspended in phosphate 
buffered saline (PBS). Peripheral blood mononuclear cells (PBMC) 
were subsequently isolated by differential sedimentation through 
Ficoll-Paque (Pharmacia LKB Biotechnology, Piscataway, NJ) 
gradients (600 x g; 30 min). The Pharmacia protocol recommends 
400 x g ficoll spin with human samples, but upon comparison 600 
x g gave better yields with equine samples. The PBMC enriched 
interface cells were washed three times with saline (150 x g; 10 
min) and resuspended in medium (RPMI-1640 supplemented with 
20 mM HEPES buffer, antibiotics, glutamine, 2-mercaptoethanol 
and fetal calf sera (FCS, 5% v/v)). Optimal culture conditions 
were determined by comparing various concentrations and 
additions or deletions of media supplements. Cell numbers and 
viability were determined and the cells resuspended at 1 x 10® 
cells/ml in medium. Cells were prepared fresh for each 
experiment, since frozen buffy coats exhibited a  loss in lytic and 
serine este rase  activity.
Lymphocyte Proliferation 
Peripheral blood mononuclear cells (PBMC; 105) were 
cultured in medium in triplicate wells of 96-well, round- 
bottomed microtiter plates (Costar, Cambridge, MA). Each virus
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and mitogen was tested at four different concentrations per 
assay. Prototype and virulent virus were added to the wells at 
1/20, 1/60, 1/200, and 1/600 dilutions of the virus stock. 
Formalin-inactivated virus was initially diluted 1/1000 with PBS 
and then added at the sam e dilutions as  live viruses. Pokeweed 
mitogen (PWM; GIBCO/BRL, Gaithersburg, MD) was added at final 
concentrations of 4, 2, 1 and 0.5pg/ml. All of the above dilutions 
were made in medium and diluted samples were added to the wells 
in 100jil volumes of medium. Unstimulated control wells 
contained cells in media only. The final volume of all cultures 
was 200pl. The plates were incubated at 39°C in a  humidified, 5% 
CO2 incubator.
Lymphocyte proliferation was measured by the incorporation 
of 3 H-thymidine into cellular DNA. The cells were pulsed with 0.5 
pCi of 3H-thymidine (New England Nuclear, Boston, MA) for 4 hours 
on the sixth day of the culture period. The best incubation time 
for proliferation was determined by comparing several time 
points. The plates were then stored frozen (-20°C) until the DNA 
was harvested onto glass fiber filter paper for liquid scintillation 
counting. The lymphoproliterative response is expressed either as  
counts per minute (CPM) or stimulation indices (SI), defined a s  the 
CPM of cells cultured with antigen or mitogen divided by the CPM 
of cells cultured in medium alone. The CPM of three replicate 
cultures for the optimal dose of antigen or mitogen were used for 
all determ inations.
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Nylon Wool T Cells 
The nylon wool columns were prepared as  described by 
Henry, et a/., 1980 in Selected Methods in Cellular Immunology.
The PBMC's were layered on the nylon wool column which retains 
the macrophages, monocytes, and B cells. The T cell enriched 
population was collected in media and washed. The stimulators 
were autologous PBMC's which were irradiated at 10? cells/ml 
with 1000 rads by either X-ray (16 1/2 min, 250 Kv, 10 mA) or 
cobalt (60Co; 30 sec). Several radiation dosed were tested in 
order to determine the optimal dose for stimulation without 
proliferation. After irradiation and washing, the autologous 
PBMC's were incubated with the virus or antigens for at least 30 
min. The nylon wool T (NWT) cells and the irradiated PBMC's were 
then cultured at a  3:1 ratio (1 x 105 NWT/well ; 3 x 104 irradiated 
PBMC/well).
Separation of Equine Lymphocytes 
The murine monoclonal antibody EqT3 which recognizes a 
cell-surface antigen on mature equine T lymphocytes was 
purchased from VMRD Inc. (Pullman, WA). Approximately 5 x 10® 
ElAV-stimulated (5 days) PBMC or NWT were resuspended in 
phosphate-buffered saline (PBS) containing goat sera  (10% v/v) 
and incubated on Ice for 30 min with the EqT3 monoclonal 
antibody. The labeled cells were washed with ice-cold PBS (3 
mis; 200 x g; 10 min; 4°C) and incubated an additional 30 min with 
a  fluorescein isothiocyanate (FITC)-conjugated anti-mouse
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immunoglobulin (Sigma). In order to determine the optimal 
working dilution, the EqT3 and the FITC were titered prior to use 
at a  fixed concentration. The cells were again washed with PBS 
and resuspended in RPMI-1640 containing goat sera (10% v/v). The 
labeled and unlabeled cells were sorted in a  Becton Dickinson 
model 440 flow cytometer. Sorted cells were collected into 15 ml 
centrifuge tubes containing ice-cold medium. Cell viability and 
percent recovery were determined for each sorted population. The 
cells were resuspended at 10® cells/ml in medium and pulsed 
with ^H-thymidine a s  described above.
Serine Esterase Assay 
Serine esterase  activity in the lymphocyte cultures was 
m easured as previously described (Horohov, eta!., 1988) with 
modifications. Stimulated cells were washed in situ with PBS 
and resuspended in 100^1 of 50 mM Tris buffer (pH 8.1) in 96-well 
plates. The cell pellets were lysed by freezing and thawing. The 
substrate, 400nM N-alpha-benzylocarbonyl-l-lysine thiobenzyl 
ester (Sigma Chemical Co., St Louis, MO) plus 400pM 5,5'-thio-bis- 
2-nitrobenzoic acid (Sigma) in 100pl Tris buffer were added to 
each well. The plates were incubated 2 hrs at room temperature 
in the dark, and the OD450 was read in an optical plate reader 
(Dynatech Laboratories, Chantilly, VA). A standard curve from 
which serine esterase units could be calculated was generated for 
each assay  using serial dilutions of trypsin (Sigma).
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Lectin-Mediated Cytotoxicity 
The PBMC's were stimulated as described above and after 6 
days the 51Cr-labeled murine A20 targets (100pCi (Na2)51C r04  
/106 cells; 2 hrs; 37°C) were added to the effectors (stimulated 
PBMC). The lectin PH A was added at 4pg/ml in order to bypass the 
need for specific recognition. These were incubated with effector 
target ratio (E:T) of 90:1, 30:1, and 10:1 for 4 hours at 39°C. The 
supernant was harvested (Skatron SCS, Nonway) and counted on a 
gamma counter to determine the amount of 5 1Cr released from the 
labeled targets. The cytolytic response is expressed as  lytic units, 
which are defined as the amount of activity in 107 effectors that 
causes lysis in 30% of the target cells.
Pony Vaccination 
To prepare the inactivated whole-virus vaccine, a  2.0 mg/ml 
solution of purified prototype EIAV was treated with 0.8% 
formaldehyde at 4°C for 24 hours, neutralized with 2% sodium 
bisulfite, and then dialyzed overnight with 0.01 M phosphate 
buffer. The EIAV envelope glycoprotein (gp 90 and gp 45) 
preparation (provided by R.C. Montelaro, University of Pittsburgh) 
was produced by fractionation of the gradient-purified EIAV by 
lentil lectin affinity chromatography, as  detailed previously 
(Montelaro, et at, 1983). The final preparations of formalin- 
inactivated virus and lectin affinity-purified envelope 
glycoproteins were then tested for residual infectious virus in 
flask cultures of FEK cells. All test for infectivity of the
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formalin-inactivated and the subunit preparations were negative. 
For immunization, the preparations were mixed with equal 
volumes of adjuvant (Syntex Laboratories, Palo Alto, CA) at final 
concentrations of 6 mg of threonyl-muramyl dipeptide per dose of 
vaccine. The final concentrations of the vaccines were 1 mg of 
formalin-inactivated prototype EIAV or 200pg of the lectin 
affinity-purified viral glycoprotein fraction.
Ponies were vaccinated at 0, 2, and 6 weeks with either 
formalin-inactivated prototype (6 ponies) or subunit (8 ponies) 
vaccines. Control ponies received either a  tissue culture sham (2 
ponies) or adjuvant (2 ponies) only.
Challenges were with the prototype or virulent strain and were 
given 12 weeks after the first dose was administered. Ponies 
were monitored for viremic and febrile episodes following 
infection (Issel, et al., 1992).
Peptides
The tymphoproliferation and serine esterase assays were 
also done by stimulating in vitro with peptides and internal 
proteins. The peptides (graciously provided by J. Ball, University 
of Pittsburgh) were selected based on predicted T cell epitopes 
(Ball, et a/., 1992), results of preliminary proliferation screens, 
and their availability. The envelope peptides were all purified 
using reverse-phase high pressure liquid chromotography (Ball, et 
a i,  1992). The gag proteins (provided by R.C. Montelaro) were 
prepared by reverse-phase HPLC (Ball, et at., 1988). Stocks were
prepared a t a  final concentration of 1 mM. For each assay  the 
stocks were diluted to 8, 5, 2.5, and 1.25 uM in culture media 
without FCS and 100pl was added to triplicate wells in 96 well 
microtiter plates. The plates were wrapped in plastic wrap and 
stored at -70°C until the day of the assay. The PBMC's or NWT's 
were resuspended in media with 10% FCS and 100pl added to 
p la tes  containing the viral an tigens, giving a  final FCS 
concentration of 5% (v/v). For lymphoproliferation assays, the 
plates were pulsed overnight (18 hrs) rather than 4 hrs as  
described above.
Chapter III
Cell-Mediated Immune R esponse of Ponies Infected With
EIAV
Introduction
Cytotoxic T lymphocytes (CTL) play an important role in the 
control and elimination of many viral infections (Larsen, et at., 
1984; Mitchell, et at., 1985). In order for a  CTL to destroy a 
virally infected cell, it must first recognize the viral protein 
fragments bound to a  major histocompatibility complex (MHC) 
class I molecule on the cell surface (Monaco, 1992). This CTL 
recognition is mediated by a membrane bound T cell receptor (TCR) 
composed of a  and p chains. The interaction of the TCR with the 
viral fragment-MHC molecule initiates a  multi-step process 
leading to the destruction of the virus infected cell.
Similarly, the induction of the CTL response also requires 
multiple steps including the activation, proliferation and 
differentiation of the CTL precursor (Horohov, et at., 1987). 
Proliferation is conveniently measured using a  3 H-thymidine 
incorporation assay. CTL precursor differentiation can be 
determined by measuring the induction of serine esterase, a 
trypsin-like enzyme found in the cytoplasmic granules of 
cytotoxic cells (Pasternack, et at., 1986), and measuring the 
lectin-mediated cytotoxicity. Here the T cell response to EIAV 
was m easured using antigen specific proliferation, serine
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esterase  activity, and lectin-mediated cytotoxicity. These 
results provide evidence of multiple CM I responses to EIAV in 
experimentally infected ponies.
R esults
PBMC from infaoted pnnifls proliferate in response  to EIAV 
s t im u la t io n :
In order to demonstrate ElAV-specific proliferation, PBMC 
from experimentally infected and control ponies were stimulated 
with various doses of whole virus (Fig 1). This 
lymphoproliferative response is representative of the responses 
observed for numerous ElAV-infected ponies. By contrast, the 
PBMC from the EIAV negative control pony did not proliferate in 
response to any dose of EIAV.
T cells from infected ponies proliferate in re sp o n se  to EIAV 
s t im u la t io n :
To determine which lymphocytes were proliferating nylon 
wool purified T cells (NWT) prepared from PBMC from infected and 
immunized ponies were stimulated in vitro with EIAV. The NWT 
from an immunized pony proliferated in a  dose-dependent manner 
following stimulation with EIAV whole virus (Fig 2). This graph is 
representative of results obtained from numerous infected and 
immunized ponies.
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Figure 1: Lymp ho proliferative response of PBMC from infected and 
control ponies. Peripheral blood was collected from an EIAV 
negative (open square) and experimentally infected pony (closed 
squares). The PBMC were incubated with EIAV whole virus and on 
day six the 3H-thymidine incorporation was m easured and and 
reported as  total CPM.
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Figure 2: Lympho pro I iterative response of NWT from an 
immunized pony. Peripheral blood was collected three months 
post immunization and the NWT incubated with EIAV whole virus 
at various dilutions. On day six. the ^H-thymidine incorporation 
was measured and reported as stimulation indices.
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T cells a re  the  proliferating cells:
While the results obtained using NWT indicated that T cells 
were responsible for the lymphoproliferative response, it 
remained possible that a contaminating subpopulation of non T 
cells were responsible. In order to confirm that T cells were 
proliferating in response to virai stimulation, virus stimulated 
cells were sorted into T cell and non T cell populations prior to 
pulsing. FACS analysis of PBMC labeled with a  monoclonal 
antibody to a  T cell antigen is illustrated in Fig 3. Using this 
reagent it was possible to identify a T cell and non T cell 
population. In order to confirm the identity of the T cell fraction, 
PBMC from normal EIAV negative ponies were stimulated with the 
T cell mitogen phytohemagglutinin (PHA). The pooled fluorescent 
labeled cells were sorted into a T cell and non T cell population 
prior to pulsing with ^H-thymidine. The T cell fraction had 
increased proliferation after stimulation (Fig 4). After 
demonstrating that T cell proliferation could be identified by 
sorting, cells from a  normal and an infected pony (one year post 
infection) were stimulated in vitro with EIAV, sorted and pulsed 
with 3H-thymidine (Fig 5). The cells from the uninfected pony and 
the non T cells all had thymidine incorporation counts under 1000 
cpm. Although not shown here, the resting or unstimulated ceils 
also had counts under 1000 cpm. In contrast, the T cells of the 
infected pony were udergoing significant proliferation with 
counts over 10,000 cpm. These results were repeated using cells 
from other infected and normal ponies.
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Figure 3: EIAV stimulated cultures may be separated into a  T cell 
and non T cell population. 1 X 10® ElAV-stimulated equine cells 
were labeled with the EqT3 monoclonal antibody and analyzed on 
the FACS 440.
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Figure 4: Thymidine incorporation by PHA stimulated T cells. 
Equine T (hatched bar) and non-T cell (solid bar) populations were 
prepared from pooled PHA-stimulated cultures by fluorescent 
activated cell sorting using a  monoclonal antibody directed 
against a common T cell antigen (EqT3). Equivalent numbers of 
cell were incubated with ^H-thymidine for four hours and then 
harvested for counting.
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Figure 5: T celts from an infected pony proliferate in response to 
EIAV stimulation. PBMC from EIAV negative and an experimentally 
infected pony were stimulated with EIAV whole virus. The T 
(hatched bar) and the non-T (solid bar) cells were separated by 
fluorescent activated cell sorting using EqT3 monoclonal antibody. 
1 X 105 cells were incubated with 3H-thymidine then harvested 
and counted. These results represent the average CPM of replicate 
wells from EIAV infected and uninfected ponies.
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PBMC from infected ponies have increased  serine e s te ra s e  activity 
in re sp o n se  to EIAV stimulation:
In order to determine if the in vitro stimulation with EIAV 
antigens lead to the generation of cytotoxic activity, PBMC from 
experimentally infected and control ponies were stimulated with 
EIAV whole virus at various doses and assayed for serine esterase 
activity (Fig 6). The serine esterase  activity detected is typical 
of the response observed with various ponies. The PBMC of the 
EIAV negative control pony (open square) had no antigen specific 
increase in serine esterase activity. However, PBMC from the 
EIAV infected pony (closed square) exhibited an antigen specific 
increase in serine esterase  activity after in vitro stimulation 
with EIAV.
Correlation of se rine  e s te r a s e  activity and  cytolytic activity:
In order to demonstrate that the increase in serine esterase 
activity was associated with the induction of cytotoxicity, PBMC 
from infected ponies stimulated in vitro with EIAV were 
assessed  for cytolytic activity using the lectin mediated 
cytotoxicity assay. A good correlation (R-0.79) was observed 
between cytolytic and enzymatic activities (Fig 7). Thus, with 
increased cytolytic activity a  similar increase in enzymatic 
activity was seen, indicating that the serine esterase  assay  could 
be used as  an index for cytolytic activity.
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Figure 6: Serine esterase activity of PBMC from an infected and 
control pony. Peripheral blood was collected from an EIAV 
negative (open square) and an experimentally infected pony (closed 
square). The PBMC were incubated with EIAV whole virus after six 
days and serine esterase activity determined. Serine esterase 
units were calculated from a  standard curve using trypsin.
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Figure 7: Correlation of serine esterase and lytic units. EIAV 
whole virus stimulated PBMC from 8 ponies two months post 
experimental infection were assessed  for cytolytic and serine 
e s te ra se  activity.
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Comparison of proliferation, serine esterase, and cvtolvtic 
activities in ponies infected with EIAV:
When PBMC from ponies experimentally infected two months 
early with EIAV were assayed for proliferation, serine esterase, 
and cytolytic induction, variations were observed (Fig 8). While 
som e ponies responded in all three assays, others had little to no 
response. Overall the immune responses correlated with the 
clinical picture. The ponies with multiple febrile episodes (ponies 
632, 830, 844) during the first two months of infection had more 
response than the ponies (ponies 823, 842, 826, 82, 831} with few 
or no febrile episodes (C.J. Issel, personal communication).
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Figure 8: Comparison of proliferation, serine esterase, and 
cytolytic activities in ponies infected with EIAV. PBMC from 
ponies experimentally infected for two months were assayed for 
proliferation (open bar), serine esterase (solid bar), and cytolytic 
(hatched bar) activities after EIAV whole virus stimulation.
35
Discussion
Viruses may be eliminated by multiple immune mechanisms, 
including neutralization by antibody, antibody dependent cell- 
mediated cytotoxicity, interferon production, or by cellular 
immune response involving sensitized T cells. During EIAV 
infection, there is no correlation between the level of neutralizing 
antibody and the control of viremia (Rwambo.ef a/., 1990). This 
indicates that in EIAV infection, as with other viral infections, 
cell-mediated immunity may be involved in d isease control. One 
in vitro m easure of T cell response expressed is antigen specific 
lymphocyte proliferation (Corradin, et a/., 1977). Lymphocytes 
from immunized or infected animals will proliferate in vitro in 
response to specific antigens to which they were sensitized to in 
vivo . This lymphocyte proliferation can be measured by 
determining the increase in DNA synthesis. Previous research has 
shown that there is an increase in lymphopro(iteration shortly 
after primary infection with EIAV and with recurrent febrile 
episodes (Kono, et a i, 1976).
Antigen specific lymphoproliferation of PBMC and NWT from 
experimentally infected ponies was used to dem onstrate EIAV 
specific cell-mediated immunity. PBMC from EIAV infected ponies 
stimulated in vitro with the virus had an antigen specific 
increase in 3 H-thymidine incorporation. Using flow cytometric 
sorting of the cells into T cell and non T cell populations, the 
proliferative response was found to be mediated by T cells .
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To further characterize this T cell proliferative response, 
serine esterase activity of stimulated cells was measured. Serine 
este rase  is localized in cytoplasmic granules of cytotoxic cells.
This enzyme has trypsin like properties and is secreted by 
cytotoxic celts during attack on target cells. The exact role of 
serine esterase is unknown, but it may function in the recycling of 
cytotoxic effector cells by detaching the effector cell from the 
target. The serine esterase activity can be measured in vitro 
using a  color metric assay  (Pasternack, et a/., 1966). in vitro 
stimulation of PBMC from EIAV infected ponies resulted in an 
antigen specific increase in serine este rase  activity, indicating 
that cytotoxic cells may be involved in the cell-mediated immune 
response to this virus.
Additional evidence that cytotoxic cells are involved, was 
provided using a  lectin-mediated cytotoxicity assay  of stimulated 
PBMC from infected ponies. The lectin phytohemagglutinin (PHA) 
is added in this assay to by-pass the need for specific MHC 
recognition. When the results from the lectin-mediated 
cytotoxicity assay and the serine esterase assay  were compared a 
good correlation was observed between cytolytic and enzymatic 
activities. Thus, with an increase in cytolytic activity a  similar 
increase in serine esterase activity was observed. This 
dem onstrates that cytolytic activity is associated with the 
induction of serine esterase. Taken together these data indicate 
that the response is cell-mediated and possibly involves cytotoxic 
T lymphocytes.
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While the precise role of these in vitro measured CMI 
responses in limiting EIAV infection remains unclear, some 
inferences may be made from the specific responses of the 8 
experimentally infected ponies. Though the immune response of 
the experimentally infected ponies exhibited considerable 
variation, the ponies that had marked in vitro responses to 
antigen stimulation also had more febrile episodes during the 
first 60 days of infection than those ponies with diminished in 
vitro responses. It is not known whether there was more 
response in vitro due to the febrile episodes or if the immune 
response in vivo was responsible for the febrile episodes. The 
latter possibility is particularly intriguing considering the 
already well-established immunopathologic com ponents of this 
d isease (Issel, et a/., 1986) and the fact that macrophages serve 
as the major target of the virus (McGuire, et at., 1986). Im mu na­
med iated lysis of infected macrophages and the subsequent 
release of pyogenic cytokines is consistent with the observed 
pathology. Additional studies on the role of cell-mediated immune 
responses in the pathogenesis of this disease are clearly needed.
In summary, these studies using PBMC and NWT's from EIAV 
experimentally infected ponies dem onstrate a  cell-mediated 
immune response. Thus, in EIAV infection as  with other viral 
infections, the CMI may be involved in the control of clinical 
disease. There is the possibility, however, that the CMI may also 
contribute to the pathogenesis a s  well. This has important 
implications for EIAV vaccine design.
Chapter IV
Cell-Mediated Immune Responaes to Equine Infectious
Anemia Vaccines
Introduction
The ability of the host's immune system to routinely control 
lentivirus replication is unique to EIAV. The immune mechanism 
responsible for controlling EIAV replication remains unknown. It 
has been proposed that the cell-mediated immune responses may 
be important since the decline in viremia does not correlate with 
the appearance of neutralizing antibodies (Rwambo, et at., 1990a). 
Immune responses mediated by T cells play an important role in 
controlling various viral infections (Larsen, et at., 1984; Mitchell, 
et at., 1985) but their role in lentivirus infections remains 
undefined (Krowka, et at., 1990). Cell-mediated immune responses 
to HIV have been detected following both infection and vaccination 
(Krowka, et at., 1990; Schrier, et at., 1989; Zarling, et at., 1986). 
Likewise, lymphoproliferative and cytotoxic responses against 
EIAV have been shown to follow EIAV infection, though the 
significance of these responses in controlling virus replication 
and d isease remains unclear (Gerencer, et at., 1989; Kono, et at., 
1976b; Shively, et at., 1982).
To investigate the role of cell-mediated immune responses 
in protection from ElAV-induced disease, the T cell responses to 
EIAV in vaccinated ponies were analyzed. The results demonstrate
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that vaccination with either formalin-inactivated whole virus or a 
glycoprotein subunit vaccine stimulated EIAV specific responses. 
While there did not appear to be any difference in the in vitro T 
cell responses induced by either vaccine, significant differences 
were observed in the response to the in vivo virus challenge.
R esults
PBMC from EIAV-vaccinated ponies proliferate in response to 
stimulation with EIAV antigens:
PBMC from control ponies (Fig 9, top) and ponies vaccinated 
with either a formalin-inactivated preparation of the prototype 
strain of EIAV (Fig 9, middle) or a  glycoprotein subunit 
preparation (Fig 9, bottom) were stimulated with EIAV and control 
antigens at various times during the vaccination protocol. None of 
the control ponies PBMC responded to EIAV stimulation prior to 
challenge. Prior to vaccination (week 0), the PBMC from the 
vaccine group also failed to proliferate in response to stimulation 
with EIAV antigens. However, by the second week post­
vaccination the PBMC from the vaccinated ponies proliferated in 
response to EIAV stimulation (p< .01, ANOVA). The 
lymphoproliferative response peaked during the sixth week, four 
weeks after the the second vaccine dose but the third vaccine 
dose did not significantly augment the lymphoproliferative 
response. Differences were not observed in the proliferative 
responses of PBMC stimulated with either prototype or virulent 
EIAV strains or with the formalin-inactivated vaccine.
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Figure 9: Lymphoproliferative responses of vaccinated and control
ponies. Peripheral venous blood was collected at various times 
from control (top panel), formalin-inactivated (middle panel), and 
subunit (bottom panel) recipients and the PBMC were incubated 
with either PWM (open square), whole prototype EIAV (open 
circle), formal in-inactivated prototype EIAV (closed circle), or 
virulent EIAV (open triangle). Control cultures contained cells 
incubated with medium (see Figure 11). All cultures were assayed 
for lymphoproliferation on the sixth day using 3H-thym idine 
incorporation and stimulation indices were calculated.
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The lymphoproliferative response to EIAV is mediated bv T cells;
In order to determine the identity of the proliferating cells, 
the EIAV stimulated cultures were labeled with a  monoclonal 
antibody and sorted into T and non T cell populations prior to 
pulsing with ^H-thymidine. The results presented in Figure 10 
demonstrate that the T cells from EIAV infected ponies and ponies 
vaccinated with each vaccine were proliferating in response to 
stimulation with EIAV. Stimulation indices for each group of 
ponies are given in Table 1 and demonstrate the T cell nature of 
the lymphoproliferative response.
PBMC from EIAV vaccinated ponies are activated in vivo, bv EIAV:
Prior to challenge with EIAV, pony PBMC incorporated only 
low levels of ^H-thymidine into their DNA in the absence of 
antigenic stimulation (Fig 11, days -7 through 83). However, upon 
in vivo challenge with EIAV, the PBMC from ponies vaccinated 
with formalin-inactivated whole virus (Fig 11, middle) and the 
subunit vaccine (Fig 11, bottom) incorporated significant levels (p 
< .001; ANOVA) of ^H-thymidine when placed into cultures 
containing medium alone on days 95 through 116. This 
spontaneous proliferation presumably resulted from the in vivo 
activation of vaccine primed lymphocytes by the EIAV challenge 
since the control ponies' PBMC did not exhibit this response
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Form. Inactlvotod
Subunit Vaoclno
Infoetod
0 2 0  40  6 0  8 0  100
Percent (%)
Figure 10: T celts proliferate in response to EIAV stimulation. 
Equine T (hatched bar) and non-T cell (solid bar) populations were 
prepared from ElAV-stimulated cultures by fluorescent activated 
cell sorting using a  monoclonal antibody directed against a 
common T cell antigen (EqT3). Equivalent numbers of cells (1 X 
105/well) were incubated with 3H-thymidine overnight and then 
harvested for counting. These results represent the percentage of 
the total CPM of the unfractioned cells.
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Table 1: Lymphoproliferative Response of Equine T Cells to EIAVa
Ponies
EIAV negative 
EIAV infected 
Subuint Vaccinated 
Form. Inactivated Vaccinated
Stimulation Indices
I -C e lls Non T-Cells
1.0 0.8
23.5 2.1
13.2 0.8
31.2 3.5
a PBM C were incubated five days with EIAV and then labelled with 
the monoclonal antibody EqT3 for fluorescent activated cell 
sorting. 10$ sorted cells were transferred to 96-well plates and 
pulsed with ^H-thymidine. Stimulation indices 
(CPM experimentai/CPMcontroi) were calculated using unstimulated 
cells as the control.
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Figure 11: PBMC from vaccinated ponies spontaneously proliferate 
following in vivo challenge with EIAV. Peripheral venous blood 
was collected from control (top panel), formalin inactivated 
vaccine recipients (middle panel), and subunit vaccinates (bottom 
panel), at various times and the isolated PBMC placed into 
cultures containing only medium. After six days in culture the 
cells were pulsed with ^H-thymidine, harvested and counted. The 
results represent the average CPM for the ponies within a  group. 
Asterisks indicate days of vaccination and the arrow indicates the 
day of challenge.
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(Fig 11, top). Both prototype (Fig 11, open circles) and virulent 
(Fig 11, closed circles) challenges stimulated this spontaneous 
lymphoproliteration response in the vaccinates, though with some 
noteworthy differences. Both viral challenges stimulated 
spontaneous proliferation of the PBMC from the formalin- 
inactivated whole virus vaccinates (Fig 11, middle) with 
somewhat higher, though not significant (p > .2), levels of 3 H- 
thymidine incorporation were observed for the PBMC from virulent 
challenged ponies. Conversely, the spontaneous ^H-thymidine 
incorporation by the PBMC from subunit vaccinates challenged 
with virulent virus was significantly less (p <.001) than that 
following prototype challenge (Fig 11, bottom).
PBMC associated serine esterase activity varies between the 
vaccine recipients following EIAV challenge:
The intracellular granules of cytotoxic T lymphocytes and 
natural killer cells contain serine esterases referred to as  
granzym es (Jenne, et a i, 1988). The activation of these cytolytic 
effector cells results in an increase in serine esterase  activity 
(Pasternack, et at., 1986; Welsh, et at., 1990). In order to 
determine if these effector cells were being activated in the 
challenged ponies, we assayed freshly isolated PBMC for serine 
esterase activity following challenge with EIAV (Fig 12). PBMC 
from the formalin-inactivated vaccine recipients (six ponies)
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Figure 12: PBMC-associated serine esterase activity from EIAV 
challenged ponies. PBMC were assayed for serine esterase 
activity one week following challenge with either prototype (open 
bars) or virulent EIAV (hatched bars). Serine esterase units were 
determined from a  standard curve using trypsin. The results 
represent the mean for PBMC from all the ponies within each 
group.
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exhibited elevated levels of serine esterase  activity following 
challenge with either strain of the virus. Likewise, the PBMC 
from the subunit vaccinated ponies (eight ponies) also exhibited 
high levels of serine esterase activity one week after challenge 
with prototype virus. However, the PBMC from the subunit 
vaccinated ponies challenged with virulent virus exhibited low 
levels of serine esterase  activity which were not different from 
the control ponies.
Formalin-inactivated whole virus vaccine recipients were 
protected:
Ponies were monitored daily for viremic and febrile 
episodes following challenge with the prototype or virulent virus 
strain. Table 2 summarizes the clinical results of challenged 
vaccinated ponies (Issel, et at., 1992). Ponies (6 ponies) receiving 
the formalin-inactivated whole virus vaccine were protected from 
clinical disease. The subunit vaccine recipients (8 ponies) were 
protected from infection with prototype challenge, but not the 
virulent challenge. The control ponies were not protected.
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Table 2: Clinical results of pony vaccination and challenge.
No Vaccines Subunit Vaccine^ FI Vaccine^
Protod Virulent6  Proto Virulent PlfltQ Virulent
Feverf C 
ViremiaO +
aControl ponies received either a  tissue culture sham or adjuvant 
at 0, 2, and 6 weeks.
bPonies were vaccinated at 0, 2, 6 weeks with 200pg of viral 
glycoprotein in MDP adjuvant.
cPonies were vaccinated at 0, 2, 6, weeks with 1mg of formalin- 
inactivated prototype EIAV in MDP adjuvant.
dPrototype-EIAV, derived from the virulent Wyoming strain of 
EIAV, was attenuated by in vitro propagation in primary fetal 
equine kidney (FEK) cells. Ponies were challenged with 10,000 
infectious doses.
6Virulent-EIAV, a pathogenic variant of prototype virus that was 
obtained from a  prototype infected pony and was propagated in 
vitro in the presence of neutralizing antibodies. Ponies were 
challenged with 10,000 infectious doses.
fFever, rectal temperature i  39°C
OViremia, determined by tissue culture and detection of viral 
antigens
Discussion
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Infection with various viruses leads to the in vivo 
activation and expansion of T lymphocytes, which proliferate in 
vitro in response to stimulation with viral antigens (Larsen, et 
al., 1984; Mitchell, et al., 1985). The in vitro 
lymphoproliferation response is mediated primarily by virus 
specific CD4+ helper T celts which provide help for the generation 
of other antiviral immune responses (Sherman, et at., 1983). Two 
groups reported that EIAV infection also leads to the development 
of an EIAV specific lymphoproliferative response which is 
mediated by T cells (Kono, et al., 1976b; Shively, et al., 1982). 
Kono and coworkers (1976b) reported that lymphocyte 
proliferative responses to EIAV antigen were detectable two 
weeks post primary infection and prior to the onset of clinical 
disease. The results presented here demonstrate that vaccination 
with either an inactivated whole virus or a  glycoprotein-enriched 
subunit vaccine stimulates T cells capable of mediating an EIAV 
specific lymphoproliferative response. Significant 
lymphoproliferative responses to EIAV were detected two weeks 
after the first dose was given. It had also been reported that T 
cell enriched lymphocyte cultures proliferate in response to EIAV 
stimulation (Shively, et al., 1982). Using a monoclonal antibody 
specific for equine T cells and a fluorescent activated cell sorter, 
we were able to demonstrate that the cells proliferating in the 
EIAV stimulated cultures were T lymphocytes. Similar results
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were obtained with PBMC from vaccinated and infected ponies.
Thus, no apparent differences were observed in the 
lymphoproliferative response induced by either vaccine or 
between vaccinated and infected ponies.
Lymphocyte biastogenesis and increased serine esterase 
activity follow in vivo challenge with infectious virus and this 
response is associated with the induction of virus-specific 
cytotoxic T cells {Biron, et al., 1986; Welsh, et at., 1990).
Likewise, the PBMC from both groups of EIAV vaccinates exhibited 
spontaneous proliferation and elevated serine este rase  activity 
following in vivo challenge with EIAV. The PBMC from control 
ponies, however, failed to respond in a  like manner. These results 
indicate that primary infection with EIAV may not be effective at 
stimulating a  cytotoxic T cell response. The blastogenic and 
serine esterase  response observed in the challenged vaccinates 
may thus represent a  memory cytotoxic cell response.
While no significant differences were detected between the 
vaccinates regarding their in vitro response to the various EIAV 
antigens, the in vivo response to the two different viral strains 
was quite different. Even though the PBMC from both groups of 
vaccinates exhibited similar levels of spontaneous proliferation 
and serine este rase  activity following prototype challenge, the 
subunit recipients' PBMC exhibited much lower levels of 3 h -  
thymidine incorporation and no elevation of serine este rases after 
virulent challenge. Thus the subunit vaccine appears to have 
stimulated a  strain specific response in contrast to the cross­
51
reactive response to the whole virus vaccine. This restricted 
response may represent a  failure of the subunit vaccine to prime 
cross-reactive T cells, particularly cytotoxic T cells, which 
would respond to virulent virus antigens. One explanation for this 
failure is that the subunit lacked sufficient quantities of the 
stimulatory antigen. A likely candidate for the missing antigens 
would by the core proteins which were much reduced in the 
subunit preparation (R. Montelaro, personal communication). Core 
proteins have been shown to serve as targets for cell-mediated 
immune responses in other lentivirus infections (Nixon, et a/.,
1988). Alternatively, the processing of the virus to generate the 
subunit vaccine could have destroyed important T cell epitopes on 
viral proteins, including the envelope proteins. Further studies 
will determine which viral antigens stimulate cell-mediated 
immune responses in infected and vaccinated ponies.
The significance of the disparity in the cell-mediated 
immune responses stimulated by the two vaccines is not yet 
known. It was recently reported that ponies receiving the whole 
virus vaccine were protected from infection by homologous virus 
(Issel, et a/., 1992). Though these ponies could be infected with a 
heterologous virus, they had reduced levels of virus replication 
and no clinical disease. Ponies receiving the subunit vaccine were 
also protected from infection with homologous virus and also 
becam e infected after challenge with the heterologous virus.
Unlike the whole virus recipients, these ponies exhibited signs of 
more serious clinical d isease than the controls. In neither case
was protection from homologous challenge associated with the 
presence of neutralizing antibodies. It is tempting to speculate 
that protection against d isease following homologous challenge 
was conferred by the induction of the cytotoxic cell response 
associated with the increased serine esterase activity. Disease 
exacerbation in the subunit recipients could have resulted from an 
inappropriate immune response featuring a  diminished cytotoxic 
cell response.
Chapter V
Cell-Mediated Immune Responae to EIAV Proteins and
Peptides In EIAV Infected and Vaccinated Ponies
Introduction
Cell-mediated immunity plays an important role in antiviral 
immune responses (Larsen, et al., 1984; Mitchell, et al., 1985). In 
1979, Zinkernagel and Doherty reported that CTL were specific for 
both viral antigens and self major histocompatibility complex 
(MHC) class I molecules. Although this MHC-restricted recognition 
has been known for som e time, until recently very little was 
known about the nature of the viral antigens recognized by the 
MHC and the CTL. Recent studies suggest that the CTL recognize 
degraded fragments of the antigen bound to an MHC class I 
molecule (Elliott, et al., 1990; Bodmer, et al., 1989; Townsend, et 
at., 1986). The current model of antigen recognition by T cells 
involves the T cell receptor (TCR) recognizing a  protein fragment 
bound to the MHC molecule (Weiss, 1989). Due to this interaction 
between TCR and antigen fragment on MHC, there is interest in 
identifying those epitopes of the antigen that are recognized by T 
cells in viral infections. Knowing the epitopes required for 
induction of cell-mediated immunity could lead to the 
development of synthetic peptide vaccines, that are specific for 
the response generated as opposed to whole virus vaccines.
The results presented in this chapter show that synthetic 
peptides of EIAV envelope glycoprotein can stimulate sensitized
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cells in vitro. The proliferative and serine esterase activity of T 
cells from infected and vaccinated ponies in response to EIAV 
peptides is used as  an index of cell-mediated immunity.
R esults
PBMC's from infected and vaccinated ponies proliferate in 
response to EIAV peptide pools:
Peptide pools diluted to various pM concentrations were 
used to stimulate PBMC from experimentally infected and whole 
virus formalin-inactivated vaccinated ponies (Fig 13). The gag 
protein pool consist of p9, pi 1, p15, p26. The gp 45 pool includes 
two peptides (R34 and 51) and the 3 gp 90 peptide poofs are 
described in Figure 14. PBMC from the EIAV negative control pony 
did not respond to any of the viral peptide pools. PBMC from 
infected and vaccinated ponies did proliferate in response to in 
vitro stimulation with EIAV peptide pools. Although some 
differences were observed between infected and vaccinated ponies 
and with the five peptide pools. To determine more specifically 
what this proliferative response is directed against, the 
individual peptides were examined.
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Figure 13: PBMC from infected and vaccinated ponies proliferated 
in response to stimulation with EIAV peptide pools. Peripheral 
blood was collected from control (solid bar), experimentally 
infected (hatched bar), and formalin-inactivated vaccinated 
(speckled bar) ponies. The PBMC were incubated with either gag 
pool consisting of p9, pi 1. p15, p26, or one of the gp 90 pools 
described in Figure 14, or gp 45 pool consisting of two peptides 
(R34 and 51). After six days in culture the cells were pulsed with 
3H-thymidine, harvested and counted. Stimulation indices 
(CPMexperimentai/CPMcontroi) werG calculated using unstimulated 
cells as  the control.
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1 YGGIPGGIST PITQQSEKSK CEENTMFQPY CYNNDSKNSM AESKEARPQE
2
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51 MNLKEESKEE KRRNDWWKIO MFLLCLAGTT GGILWWYEGL PQQHY1GLVA
S3
4 5B
101 1GGRLNGSGQ SNAIECWGSF PGCRPFQNYF SYETNRSMHM DNNTATLLEA
10V
151 YHREITFIYK SSCTDSDHCQ EYQCKKVNLN SSDSSNSVRV EDVTNTAEYW
 ZZZ----------
9V
/ / / x / x z / y y z / X i
201 GFKWLECNQT ENFKTILVPE NEMVNINDTD TWIPKGCNET WARVKRCPID
V3A
251 ILYGIHPIRL CVQPPFFLVQ EKGIADTSR1 GNCGPTIFLG VLEDNKGWR
V4A ZZ2ZZZZZZZZ22-------------
V3B V4B
301 GDYTACNVRL NINRKDYTG1 YQVPIFYTCT FTN1TSCNSK PIISVIMYET
V5C —
351 NQVQYLLCNN NNSNNYNCW QSFGVIGQAH LELPRPNKRI RNQSFNQYNC
401 SINNKTELET WKLVKTSGVT PLPISSEANT GLIRHKR
12
Figure 14: EIAV gp90 envelope peptide pools. Pool one (hatched 
bars) contains peptides 2, V3A, V3B, V4, 12, pool two (striped 
bars) contains peptides 4, V4A, V4B, 5B, 9V, and pool three 
(speckled bars) contains peptides V5B, V5C, 10V.
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NWT's from infected and vaccinated ponies proliferate in response 
to EIAV peptide stimulation:
Nylon wool purified T cells (NWT) from prototype infected, 
virulent infected, and formalin inactivated whole virus vaccinated 
ponies were stimulated in vitro with EIAV envelope peptides and 
gag proteins (Table 3 & 4). NWT from the EIAV negative control 
pony did not proliferate following virus or peptide stimulation 
(data not shown). In contrast, NWT from all of the vaccinated and 
infected ponies responded to stimulation with whole virus.
However, the proliferative response to the individual proteins and 
peptides was variable. Table 3 contains the lymphoproliferative 
results for the envelope gp 90 peptides. While the ponies 
exhibited different recognition patterns, som e trends were noted.
All of the ponies responded to the peptide V5B and the four 
prototype infected ponies responded to peptides 2 and 4 located 
near the amino terminus. Table 4 shows the proliferative 
response to the gag proteins and the gp 45 peptides. While NWT 
from all of the prototype-infected ponies responded to the four 
gag proteins, there was only minimal stimulation for the other 
ponies tested. There was little to no response to the gp 45 
peptides amongst any of the ponies.
58
Table 3: NWT from infected and vaccinated ponies proliferate in 
response to stimulation with EIAV envelope gp90 peptides. 
NWT and irradiated autologous PBMC were cultured at 3:1 
ratio with various envelope peptides. On day six, the 3H- 
thymidine incorporation was m easured and stimulation 
indices calculated. The stimulation indices of four doses 
were averaged and the following rating system used:
+++++ SI » 4 ;  + + + + S li.4 ; + + + S li3 ;  + + S li ,2 ;  + S I> 1 ; 
+/- SI -  1.
FI Vaccine Prototype Challenge PV Challenge
P on v# 02 OH 91 95 11 »3 IS 17 IK
E1AX
pd 90 Pentides
_aa&.
+++++ +++++ ++ ++++ ++ + ++++ + + + + + +
2 (22-36) + - + ++ ++ + + ++ - - -
4 (50-79) - • ++++ ++ + ++ +/- +++ m
5B (92-105) +++ • - +/- +++ + w- w +/-
9V (199-173) - +++ w- ++++ ++ + - - -
I0V (171-190) - +/- - + ++ + ++ - ++ +
V3A (241-252) ++ +/- - + ++ * + +/- -
V3B (254-266) + + + + + + ++ ++ ++ + +/- ++ -
V4 (265-299) + + + + + + + +++ - +/- - +/-
V4A (265-284) ++++ +++ +++ +/- ++ w ++ ■ +/-
V4B (281-299) W- ++ + w- +++ - +/- + -
V5C (305-316) +/- +/- ++ ++ ++ - ++ - -
V5B (312-328) ++++ ++++ +++ ++++ + +++ +++ ++++ +/-
12 (424-447) m - m * +/- +/- • - *
cn
CD
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Table 4: NWT from infected and vaccinated ponies proliferate in 
response to stimulation with EIAV gag proteins and envelope 
gp45 peptides. NWT and irradiated autologous PBMC were 
cultured at 3:1 ratio with various envelope peptides. On day 
six, the 3 H-thymidine incorporation was measured and 
stimulation indices calculated. The stimulation indices of 
four doses were averaged and the following rating system 
used; +++++ SI » 4 ;  ++++ SI 4; +++ SI z. 3; ++ SI i  2;
+ SI >1; +/- SI -  1.
Ponv# 
EIAY
gag Proteins
P»
pH 
pl5 
p26
gp 45 peptides 
aa#
pep 51 (534-547)
R32 (522-534)
FI Vaccine
£2 Oil
+++++ +++++
+++
Prototype Challenge
21___ 25___11___12
PV Challenge
15 17 18
++++ ++ ++++ +++++ +
+++ +/-
+++ ++ ++ ++
++ + + ++++
++  ++ +++ +++
+/- +/-
+++
+/-
++ +/-
+ /- +/*
G>
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NW Ts from infected and  vaccinated ponies have increased  serine 
e s te ra s e  activity in response  to EIAV peptide stimulation:
NWT from infected and vaccinated ponies were stimulated 
with EIAV envelope peptides and gag proteins at various doses and 
assayed for serine esterase activity (Fig 15, 16, 17). NWT from 
the EIAV negative control pony had no antigen specific increase in 
serine esterase activity (data not shown). In contrast, all of the 
infected and vaccinated ponies responded to in vitro stimulation 
with EIAV whole virus. However, the serine esterase response of 
NWT from the infected and vaccinated ponies were variable. The 
prototype infected ponies had increased activity to the gag 
proteins, some activity to the envelope gp 45 peptides, and some 
response to the gp 90 peptides near the amino terminus (Fig 15).
The formalin-inactivated vaccinated ponies had increased activity 
to the envelope gp 90 peptides located between amino acids 92 
and 299, the infected ponies had little response in this region (Fig 
16). The virulent challenged ponies had increased activity to the 
envelope gp 90 peptides located near the amino terminus and to 
the gag proteins (Fig 17).
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Figure 15: NWT-associated serine esterase activity from EIAV
prototype infected ponies. Nylon wool purified T cells and 
irradiated autologous PBMC were cultured at 3:1 ratio with EIAV 
peptides. After 6 days, the cells were assayed for serine esterase 
activity. Serine esterase units (SEU ) were determined from a 
standard curve using trypsin. The corrected S E U  (SEUexperlmentai - 
SEU controi) were calculated using unstimulated cells as  the 
control.
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Figure 16: NWT-associated serine esterase activity from EIAV
formalin-inactivated vaccinated ponies. Nylon wool purified T 
cells and irradiated autologous PBMC were cultured at 3:1 ratio 
with EIAV peptides. After 6 days, the cells were assayed for 
serine esterase activity. Serine esterase units (SEU ) were 
determined from a standard curve using trypsin. The corrected 
S E U  (SEUexperimentai * S E U Control) were calculated using 
unstimulated cells as  the control.
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Figure 17: NWT-associated serine esterase  activity from EIAV
virulent infected ponies. Nylon wool purified T cells and 
irradiated autologous PBMC were cultured at 3:1 ratio with EIAV 
peptides. After 6 days, the cells were assayed for serine esterase 
activity. Serine esterase units (SEU) were determined from a 
standard curve using trypsin. The corrected SEU (SEUexperimentai - 
SEUcontrol) were calculated using unstimulated cells as  the 
control.
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Discussion
Immune responses mediated by T lymphocytes play 
important roles in controlling viral infections, but the ability of 
these CMI responses to control EIAV disease is not clear. 
Lymphocytes from sensitized animals will proliferate in response 
to specific antigens. In order to determine which antigen epitopes 
are  responsible for this specific response, synthetic viral 
peptides may be used for antigen specific proliferation. Synthetic 
viral peptides have been shown to induce an antigen specific T cell 
proliferation with cells from HIV infected subjects (Berzofsky, et 
at., 1991; Krowka, et at., 1990; Schrier, et at., 1989; Berzofsky, et 
at., 1988).
EIAV specific cell-mediated immunity was dem onstrated by 
antigen specific proliferation of NWT from infected and 
vaccinated ponies in response to viral proteins and peptides. The 
formalin inactivated vaccine recipients had little proliferative 
response to the gag proteins compared to the infected ponies.
This may be because with the formalin-inactivated prototype 
virus the internal gag proteins were not processed or presented on 
the cell surface in the sam e manner a s  infectious viral particles.
In contrast, the vaccinated ponies lymphocytes responded 
vigorously to the external envelope proteins. The envelope gp 90 
peptide V5B is located in a  region predicted to be exposed as  an 
antigenic loop (Bail, et at., 1992). The lymphoproliterative results 
indicate that this peptide may be important in the CMI response,
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even though this region was not utilized as a  B cell epitope (Ball, 
et at., 1992). Although the gp 45 peptides R32 and 51 are part of 
the monoclonal binding site (Chong, et at., 1991), little T cell 
response was observed. These differences indicate that the B and 
T cell epitopes are not the same. When the B and T cell epitopes 
were compared for the sam e pony no overlap was observed 
(Montelaro, personal communication).
To further characterize this proliferative response to EIAV 
peptides, the serine esterase  activity of stimulated NWT was 
measured. NWT from infected and vaccinated ponies responded 
with increased serine esterase  activity to in vitro stimulation 
with a  panel of EIAV peptides . Thus, indicating that cytotoxic T 
cells may be involved in the CMI response to EIAV. The results 
show that the prototype infected, virulent infected, and the 
vaccinated ponies have different serine esterase responses to the 
panel of peptides and proteins. The prototype challenged ponies 
demonstrated an elevated serine esterase response to the gag 
proteins but not the envelope peptides. This may be because the 
gag response is to the whole protein with multiple epitopes as 
opposed to individual peptide response. Further studies will need 
to identify the gag epitopes. Both the serine esterase  and the 
proliferative response with vaccinated ponies dem onstrate that 
the formalin inactivated vaccine failed to stimulate a  CMI 
response directed against the gag proteins. As stated above these 
internal proteins may not be presented with an inactivated whole 
virus vaccine. The virulent infection stimulated a  greater serine
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esterase response than the whole virus vaccine, but less than the 
prototype infection. At this time it is not known if there are 
differences in the core protein of the two virus strains . The 
prototype infected ponies had increased proliferation and serine 
esterase  activity with the gag proteins. While the virulent 
infected and the vaccinated ponies had different response profiles 
to proliferation and serine esterase. This may indicate that the 
proliferation and serine esterase  assays are detecting different 
subsets of T lymphocytes that are responding to peptide 
stimulation. The prototype infected ponies proliferative and 
serine esterase responses to gag proteins may be to different 
epitopes, again indicating the need to identify gag epitopes. The 
proliferative and serine esterase  results show that sensitized 
ponies responded to in vitro stimulation with EIAV gag proteins 
and envelope peptides, therefore indicating that the response is 
cell-mediated and may involve cytotoxic T lymphocytes.
In summary, these studies using a  panel of synthetic viral 
proteins and peptides to stimulate NWT from vaccinated and 
challenged ponies demonstrate a cell-mediated immune response.
Thus EIAV like other viral infections, T cells are able to recognize 
and respond to antigen fragments and this response may be 
important in d isease control.
Chapter VI
Conclusions
Equine infectious anemia has been recognized as a viral 
d isease of horses since the early 1900 (Vallee and Carre, 1904). 
While clinical manifestations of this d isease are severe, including 
cycles of fever, depression, edema, weight loss, acute hemolytic 
anaemia, and decreased platelet count (Issel, et a/., 1984), EIAV 
is unique among lentiviruses in that the infected host routinely 
brings plasma viremia and clinical d isease under immunological 
control (Montelaro, et at., 1984). EIAV thus provides a  useful 
model for evaluating which host immune responses are 
responsible for conferring immunological control of a  persistent 
lentivirus infection. There is evidence that cell-mediated 
immunity plays an important role in the control of this disease. 
When treated with immunosuppressive drugs horses which were 
asymptomatic carriers have episodes of viremia and clinical 
disease, suggesting CMI involvement (Kono, et at., 1976a).
Likewise, foals with CIO fail to clear EIAV viremia, while normal 
foals become inapparent carriers (McGuire, et at., 1990; Perryman, 
et at., 1988). Additional support for CMI involvement in viral 
control is there is no correlation between decreased viremia and 
the level of neutralizing antibodies (Rwambo, et at., 1990a).
Further evidence that cellular immunity is important for d isease 
control com es from studies of antigen specific proliferation of
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lymphocytes from EIAV infected horses (Kono, et at., 1976b;
Shively, et at., 1982). Together these findings provide in vivo and 
in vitro evidence of a  role for cell-mediated immunity in the 
control of EIAV replication during the afebrile carrier state.
The work presented here provides further evidence that CMI 
is important in the d isease control in EIA. Antigen specific 
lymphoproliferation of PBMC and NWT from experimentally 
infected ponies demonstrated EIAV specific cell-mediated 
immunity. Positive identification that the proliferating cells 
were T cells was provided by FACS sorting. An indication of 
cytolytic cell induction was also obtained using a colormetric 
assay  for serine esterases. The serine esterase activity 
correlated with lectin-mediated cytolytic activity, indicating 
that cytotoxic cells were involved. These in vitro responses 
provide further support for a  CMI role in disease control in 
infected ponies, but it is not known how this correlates in vivo.
To investigate the role of ceil-mediated immune responses in 
protection from EIAV induced disease, the T cell responses to 
EIAV in vaccinated ponies were analyzed. Differences in 
lymphoproliferative responses were not observed between 
vaccinated and infected ponies. However, following challenge the 
vaccinated ponies exhibited spontaneous proliferation and 
elevated serine esterase  activity which was not observed in 
control ponies. This spontaneous response may represent a 
memory cytotoxic cell response induced by the vaccine. The 
formalin inactivated whole virus vaccine and the subunit vaccines
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showed no significant differences in their in vitro response to 
various EIAV antigens, though the in vivo response to the virulent 
and prototype challenges was different. After virulent challenge 
the subunit vaccine recipients' PBMC exhibited lower proliferation 
and no increase of serine esterase activity, while the prototype 
challenge both vaccines exhibited similar levels of response. This 
restricted response may represent a  failure of the subunit vaccine 
to prime cross-reactive cytotoxic T cells. The subunit vaccine 
had diminished amounts of EIAV core proteins which may be 
important antigens for inducing a  cross-reactive response.
However, T cells from a formalin-inactivated vaccine recipient 
failed to respond to in vitro stimulation with the gag proteins, 
indicating that these proteins may not have been responsible for 
the cross-reactive response. The protection observed with the 
formalin inactivated vaccine following challenge could be due to 
internal proteins other than gag. Another alternative is that the 
external proteins on the surface of a  whole virus vaccine differ 
from the purified glycoproteins in the subunit vaccine. Since the 
formalin inactivated ponies T cells showed proliferative response 
to several of the envelope gp 90 peptides, this possibility merits 
further investigation.
In conclusion the results presented here show that infected 
and vaccinated ponies demonstrate an EIAV specific celt-mediated 
immunity. These data demonstrated that T cells were 
proliferating, but the major question left to answer is which 
subset of T cells. The lymphoproliferative response to virus may
72
be more than one group of T cells, the fact that the proliferation 
and serine esterase response to peptides were different supports 
this concept. It is possible that even different subsets of T helper 
cells are stimulated. The results show that the B and T cell 
epitopes are different, therefore there may be separate epitopes 
for each subset of T cells. Knowing which epitope induces the 
immune response needed for protection, is important for designing 
future EIAV vaccines. As was seen with the subunit vaccine, 
induction of the inappropriate immune response may result in 
exacerbation of disease.
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